108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
M.C. Garassino,J. Mazieres, M. Reck,C. Chouaid,H. Bischoff,N. Reinmuth, L. Cove-Smith, T. Mansy,D. Cortinovis,M.R. Migliorino, A. Delmonte,J. Garcia Sánchez, L.E. Chara Velarde, R. Bernabe,L. Paz-Ares,I. Diaz Perez, N. Trunova, K. Foroutanpour,C. Faivre-Finn ANNALS OF ONCOLOGY（2022）
AI 理解论文
溯源树
样例
